MARKET

FWBI

FWBI

First Wave Biopharma Inc
NASDAQ
1.950
+0.010
+0.52%
After Hours: 2.000 +0.05 +2.56% 19:49 06/02 EDT
OPEN
1.920
PREV CLOSE
1.940
HIGH
2.220
LOW
1.900
VOLUME
204.70K
TURNOVER
0
52 WEEK HIGH
79.80
52 WEEK LOW
1.772
MARKET CAP
3.54M
P/E (TTM)
-0.0935
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
Gamida Cell Appoints Terry Coelho As CFO, Effective Immediately
Benzinga · 05/22 12:05
Expert Ratings for First Wave BioPharma
Benzinga · 05/15 15:01
HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Lowers Price Target to $10
Benzinga · 05/15 10:43
First Wave Bio (FWBI) Receives a Buy from H.C. Wainwright
TipRanks · 05/15 10:25
--HC Wainwright Adjusts First Wave BioPharma Price Target to $10 From $14, Maintains Buy Rating
--HC Wainwright Adjusts First Wave BioPharma Price Target to $10 From $14, Maintains Buy Rating
MT Newswires · 05/15 07:49
BRIEF-First Wave Biopharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial In Cystic Fibrosis
Reuters · 05/11 12:37
5 Analysts Have This to Say About First Wave BioPharma
Benzinga · 04/26 21:01
More
About FWBI
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. It is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.

Webull offers kinds of First Wave BioPharma Inc stock information, including NASDAQ:FWBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FWBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FWBI stock methods without spending real money on the virtual paper trading platform.